Articles tagged "Mixed chimerism"

2021 American Transplant Congress
Selective Bcl-2 Inhibition for Induction of Mixed Chimerism and Renal Allograft Tolerance without Myelosupression
G. Lassiter¹, T. Hirose¹, H. Sasaki¹, D. Ma¹, T. Oura¹, A. Dehnadi¹, A. Cosimi¹, P. Cippa², T. Fehr³, T. Kawai¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland, ³Division of Nephrology, University of Zurich, Zurich, Switzerland
*Purpose: Immunologic tolerance of renal allograft has been achieved by induction of hematopoietic chimerism through donor bone marrow transplantation (DBMT). The myeloablative and genetic toxicity…
2021 American Transplant Congress
Effects of IL-2 and/ or Anti-IL6R Therapy on Long-term Cardiac Allograft Survival in Non-Human Primates (NHPs)
C. L. Miller, K. J. Ahrens, J. M. O, P. M. Patel, J. A. Morrissette, D. Becerra, T. Costa, A. Dehnadi, I. M. Hanekamp, G. Benichou, J. C. Madsen
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
*Purpose: Cardiac allograft tolerance in NHPs has been achieved by our group using a mixed chimerism model with allogeneic bone marrow transplant after non-myeloablative conditioning…
2021 American Transplant Congress
Successful Induction of Hematopoietic Chimerism by Dual Inhibition of Mcl-1 and Bcl-2 Without Myeloablative Treatments in Nonhuman Primates
T. Hirose, D. Ma, G. Lassiter, T. Kawai
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
*Purpose: Induction of hematopoietic chimerism by donor bone marrow transplantation (BMT) is essential for achievement of allograft tolerance in clinical HLA mismatched kidney transplantation, while…
2020 American Transplant Congress
Interim Experience in a Phase 3 Prospective, Randomized, Multi-Center, Open-Label, Controlled Trial of Cellular Immunotherapy with MDR-101 for Induction of Immune Tolerance in Recipients of HLA-Matched, Living Donor Kidney Transplants
D. Kaufman¹, J. Piper², M. Stegall³, S. Akkina⁴, E. Marin⁵, A. Gaber⁶, Y. Qasi⁷, T. Srinivas⁸, D. Alonso⁹, A. Patel¹⁰, M. Laftavi¹¹, A. Shah¹², S. Collette¹³, E. Stites¹⁴, K. Chavin⁸, S. Crowley¹⁵
¹UW, Madison, WI, ²INOVA, Fairfax, VA, ³Mayo, Rochester, MN, ⁴LUMC, Chicago, IL, ⁵Yale, New Haven, CT, ⁶Houston Methodist, Houston, TX, ⁷USC, Los Angeles, CA, ⁸UH Cleveland, Cleveland, OH, ⁹Intermountain, Murray, UT, ¹⁰SBMC, Livingston, NJ, ¹¹UH Upstate, Syracuse, NY, ¹²TJU, Philadelphia, PA, ¹³CIUSSS, Montreal, QC, Canada, ¹⁴UCH, Denver, CO, ¹⁵Medeor, San Francisco, CA
*Purpose: The goals of tolerance in patients with kidney transplants (KTxp) are to eliminate the lifelong need for immunosuppressive drugs (IS) and to prevent graft…
2020 American Transplant Congress
Orthogonal IL-2 Cytokine-Receptor Pair Capable of Selective Expansion of Regulatory T Cells Facilitates Alloengraftment
T. Hirai¹, F. Simonetta², L. L. Su³, L. Picton³, J. Baker², J. Lin⁴, P. Li⁴, W. J. Leonard⁴, K. C. Garcia³, R. S. Negrin²
¹Department of Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA, ³Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University, Stanford, CA, ⁴Laboratory of Molecular Immunology, National Institutes of Health, Bethesda, MD
*Purpose: Adoptive transfer of regulatory T cells (Tregs) has been shown to improve alloengraftment in animal models. However, ex vivo Treg expansion for the purpose…
2020 American Transplant Congress
Induction of Delayed Immune Tolerance after Reconstructive Transplantation by Combining Donor Bone Marrow Transplantation and High-Dose Cyclophosphamide Treatment
Y. Guo¹, F. Messner¹, B. Oh¹, G. Furtmüller¹, W. Lee¹, D. Cooney¹, L. Luznik², G. Brandacher¹
¹Plastic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Hematology, Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Immunosuppression avoidance by induction of immune tolerance represents a primary goal in the field of transplantation. Yet, success of this concept relies on extensive…
2020 American Transplant Congress
Inducing Donor MHC Chimerism with Bone Marrow Derived Exosomes in Non-Human Primates
P. M. Patel¹, B. A. Gonzalez Nolasco¹, J. A. Morrissette¹, A. Prunevieille¹, K. J. Ahrens¹, J. M. O¹, D. C. Becerra¹, G. Benichou¹, J. C. Madsen²
¹Surgery, Center for Transplantation Sciences, Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²Surgery, Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, MA
*Purpose: Cardiac allograft tolerance in non-human primates (NHPs) has been achieved by our group via hematopoietic mixed chimerism consisting of an allogeneic bone marrow (BM)…
2019 American Transplant Congress
MHC Cross-Dressing in Mixed Hematopoietic Chimerism
B. Gonzalez Nolasco¹, M. Wang¹, W. Orent¹, A. Prunevieille¹, K. Pruner¹, J. O¹, J. Paster¹, J. C. Madsen², G. Benichou¹
¹Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Department of Surgery, Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA
*Purpose: Achieving specific long-term allograft survival without ongoing immunosuppression is one of the main objectives in transplantation. Mixed hematopoietic chimerism is a strategy that has…
2019 American Transplant Congress
Bcl-2/Bcl-xL Inhibition by Navitoclax vs. Bcl-2 Alone Inhibition by Venetoclax for Induction of Mixed Chimerism in Non-Human Primates
H. Sasaki¹, D. Ma¹, T. Oura¹, A. Dehnadi¹, I. Rosales², B. Cosimi¹, P. Cippa³, T. Fehr³, T. Kawai¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²Pathology, Massachusetts General Hospital, Boston, MA, ³Medicine, University of Zurich, Zurich, Switzerland
*Purpose: We recently demonstrated that a specific Bcl-2 inhibitor, Venetoclax, can promote mixed chimerism and renal allograft tolerance in non-human primates (NHPs) with reduced myelosuppressive…
2019 American Transplant Congress
Donor-Specific Tregs Prolong Peripheral Chimerism in Baboons Receiving GalTKO hCD47-tg Porcine Peripheral Blood Stem Cells
N. P. Llore¹, J. Stern¹, G. Pierre¹, E. Lopes¹, D. Ekanayake-Alper¹, P. Alonso-Guallart¹, K. Bruestle¹, H. Sakai¹, D. Ayares², M. Lorber², R. Hawley¹, D. H. Sachs¹, M. Sykes¹, A. D. Griesemer¹
¹Columbia Center for Translational Immunology, New York, NY, ²United Therapeutics, Silver Springs, MD
*Purpose: We have previously evaluated the ability of transplantation of polyclonal expanded recipient T regulatory cells to prolong xenogeneic chimerism and skin grafts after transplantation…

1
2
3
…
6
Next Page »